AIM logo

AIM AIM ImmunoTech Inc.

New York Stock Exchange Arca · Biotechnology · Healthcare

$0.11
-0.01 (-4.50%)

AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and …

Market Cap: $4.57Maimimmuno.com

Price

No data yet.

Social Signal Score

43
5d
30
1 mentions
—
30d
45
4 mentions
—
60d
49
12 mentions
—
90d
47
24 mentions
—
news: 24

Analyst Ratings

3 analysts
Buyconsensus
Strong Buy 0Buy 3Hold 0Sell 0Strong Sell 0

Revenue

$22.0K+37.50%
$0.00$80.0K$160.0K$240.0K
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-7.74
$-9.25–$-6.24
1 analysts
FY2026
$-0.78
$-0.93–$-0.63
1 analysts
FY2027
$-0.37
$-0.44–$-0.30
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Thomas K. Equels
Sector
Healthcare
Industry
Biotechnology
Employees
19
Beta
1.31
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-67.46
aimimmuno.com